HIF-1α

HIF-1α (Hypoxia-Inducible Factor-1α) is a master transcription factor that coordinates cellular adaptation to reduced oxygen availability by regulating the expression of hypoxia-responsive genes involved in oxygen homeostasis, angiogenesis, and metabolic adaptation^[1][2]. Mechanistically, HIF-1α activates transcriptional programs that increase glucose uptake, glycolytic flux, and mitochondrial adaptation, thereby enabling cells to maintain energy production under hypoxic conditions^[3][4]. Through these metabolic and vascular responses, HIF-1α serves as a central regulator of hypoxia signaling and integrates crosstalk with pathways including PI3K-mTOR, NF-κB, and ERK signaling networks^[5]. In disease settings, HIF-1α is frequently activated within the hypoxic tumor microenvironment, where it promotes angiogenesis, metabolic reprogramming, immune modulation, tumor progression, and resistance to therapy^[6][7][8]. Experimental studies further demonstrate that HIF-1α regulates glycolytic gene expression and contributes to the adaptation of cancer cells to intratumoral hypoxia, making it a widely used molecular target in cancer biology research^[3][4]. Compared with related isoforms, HIF-1α and HIF-2α share overlapping functions in hypoxic adaptation but exhibit distinct regulatory and biological roles; HIF-1α is more strongly associated with acute hypoxic responses and glycolytic regulation, whereas HIF-2α preferentially supports chronic hypoxia responses, vascular remodeling, and specific metabolic programs^[9][10][11]. For experimental applications, HIF-1α remains an important pharmacological target, and small-molecule inhibitors are extensively investigated to dissect hypoxia-driven signaling and tumor progression mechanisms^[12].